Ovid Therapeutics Inc. is a biopharmaceutical company developing small molecule medicines for brain disorders characterized by neuronal hyperexcitability. The company focuses on neurological and neuropsychiatric conditions, including drug-resistant focal onset seizures, developmental and epileptic encephalopathies, tuberous sclerosis complex, infantile spasms, and psychosis associated with Parkinson’s disease, Lewy body dementia, and schizophrenia. Its pipeline includes OV329, a next-generation GABA-aminotransferase inhibitor, and OV4071, a direct activator of the KCC2 transporter. Ovid targets fundamental biological mechanisms such as neurotransmitters and dysregulated ion channels to address unmet needs in epilepsy and psychosis. The company was founded in 2014 and advances clinical-stage programs that offer differentiated mechanisms of action for these conditions.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage ovidrx.com
Sector Healthcare IR page investors.ovidrx.com/overview/default.aspx
Tags
neurology, neuropsychiatry, epilepsy, seizure disorders, schizophrenia, parkinson's disease psychosis, small molecule drugs, ion channel modulation, kcc2 activation, gaba-aminotransferase inhibition, OV329, OV4071
Press page —

Metrics

Valuation  
Market cap $ 469.915M
Market cap (USD) $ 469.915M
P/E -10.90
PEG —
P/BV 2.37
P/S 64.80
P/OCF -8.13
P/FCF -12.26
Dividend yield —
Turnover / mcap —
Returns  
ROE -17.5%
ROI -13.4%
ROIC -24.6%
Profit margin -240.1%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 4
Quality score -35.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016
Revenue 7.252M 566K 391.695K 1.503M 208.383M 12.617M — — — —
Net profit -17.414M -26.433M -52.339M -54.169M 122.835M -81.036M -60.461M -51.98M -64.806M -22.414M
Free cash flow -38.334M -56.027M -45.821M -56.452M 118.428M -51.711M -51.148M -45.592M -31.509M -17.832M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016
Share price 1.63 0.93 3.22 1.86 3.21 2.31 4.15 2.42 9.87 —
Price performance 12m 0.75 -0.71 0.73 -0.42 0.39 -0.44 0.72 -0.75 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — — — — — 0.00 16.5M 16M 14.8M 13.4M
Cash and deposits (USD) 51.9M 87.1M 36.5M 41.9M 72M 188M 44.9M 27M 26.3M 13.2M
Intangible assets (USD) 110,074 124,194 391,872 467,000 319,000 164,000 222,100 182,974 100,000 0.00
Right-of-use assets (USD) — — — — — 0.00 14.9M 13.9M 12.8M 11.6M
Cash flow detail
Operating cash flow (USD) -17.8M -31.5M -45.6M -51.1M -51.6M 119M -55.2M -45.8M -56M -38.3M
Purchases of property, plant and equipment (USD) -30,364 -38,907 -33,871 -57,156 -127,240 -184,008 -1.22M -40,308 -71,000 0.00
Share-based compensation (USD) 3.64M 6.4M 7.06M 5.21M 7.53M 5.05M 6.56M 7.29M 6.28M 4.81M
Free cash flow (OCF - PPE - intangibles) (USD) -17.8M -31.5M -45.6M -51.1M -51.7M 118M -56.5M -45.8M -56M -38.3M
Income detail
Research and development expense (USD) 9.59M 50M 33.8M 42.2M 63.4M 46.9M 24.6M 28.6M 36.8M 25.6M
↳ 5y CAGR +57.2% +37.4% -13.2% -3.3% -2.7% -16.6%
Total comprehensive income (USD) — -64.8M -52M -60.5M -81M 123M -54.2M -52.3M -26.5M -17.6M
Comprehensive income to owners (USD) — -64.8M -52M -60.5M -81M 123M -54.2M -52.3M -26.5M -17.6M
Reported Mar 29, 2018 Mar 7, 2019 Mar 7, 2019 Mar 11, 2020 Mar 15, 2021 May 10, 2022 Mar 13, 2023 Mar 8, 2024 Mar 11, 2025 Mar 18, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

•OV329 is advancing in a global, Phase 2 focal epilepsy study expected to read out in H2 2027

•Ovid is enrolling patients in ongoing photosensitivity study intended to demonstrate the anticonvulsant effect of OV329; results expected in early 2027

•OV4071, the first-ever oral KCC2 direct activator, continues to progress in a Phase 1 single- and multiple-ascending dose study; translational ketamine challenge study ready for initiation

•Advancement of a pediatric formulation of OV329 is on track and Company plans to initiate a study in TSC-associated seizures before year-end 2026, representing the first indication in a broad potential DEE franchise

•Cash, cash equivalents and marketable securities were $161.4 million as of September 30, 2026; expected financial runway into 2029

NEW YORK, November 10, 2026 – Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today provided business updates including financial results for the third quarter ended September 30, 2026.

November 5, 2026

NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today announced that the Company’s management will participate in three upcoming investor conferences:

  • Guggenheim 3rd Annual Healthcare Innovation Conference – Tuesday, November 10 at 8:30 am ET

  • Stifel 2026 Healthcare Conference – Wednesday, November 11 at 3:20 pm ET

  • UBS European Healthcare Conference – Monday, November 16 at 2:40 pm GMT

Webcasts of the presentations can be accessed through the Events & Presentations section of the company’s website at investors.ovidrx.com . An archived replay of the webcasts will be available on the Company’s website following the live presentation for approximately 30 days.

About Ovid Therapeutics

Ovid Therapeutics Inc. is a New York-based biopharmaceutical company dedicated to pioneering better, gentler medicines for the brain. The Company discovers and develops differentiated, small molecule medicines for neurological and neuropsychiatric disorders with great unmet need. Ovid is developing: OV329, a next-generation GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant FOS and DEEs, including TSC and IS; and OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. For more information about these and other Ovid research programs, please visit www.ovidrx.com .

September 3, 2026

NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today announced that the Company’s management will participate in two upcoming investor conferences:

  • Cantor Global Healthcare Conference – Wednesday, September 9 at 2:10 pm ET
  • H.C. Wainwright 28th Annual Global Investment Conference – Monday, September 14 at 11:30 am ET

Webcasts of the presentations can be accessed through the Events & Presentations section of the company’s website at investors.ovidrx.com . An archived replay of the webcasts will be available on the Company’s website following the live presentation for approximately 30 days.

About Ovid Therapeutics

Ovid Therapeutics Inc. is a New York-based biopharmaceutical company dedicated to pioneering better, gentler medicines for the brain. The Company discovers and develops differentiated, small molecule medicines for neurological and neuropsychiatric disorders with significant unmet need. Ovid is developing: OV329, a next-generation GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant FOS and DEEs, including TSC and IS; and OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. For more information about these and other Ovid research programs, please visit www.ovidrx.com

Prompts

Ovid Therapeutics Inc. (ticker OVID), listed in United States.

ETFs Holding Ovid Therapeutics Inc.

ETF Weight in ETF Shares Market value As of
VFMO 0.06% 440,411 $ 1.176M Aug 31, 2026
AVSC 0.02% 285,488 $ 685.171K Nov 16, 2026
RESM 0.01% 197 $ 529.93 Jun 30, 2026
MSSM 0.00% 10,156 $ 27.117K Aug 31, 2026
DFAS 0.00% 44,904 $ 114.505K Nov 12, 2026
BSVO 0.00% 51,234 $ 110K Nov 18, 2026